This HTML5 document contains 33 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n8http://linked.opendata.cz/resource/drugbank/drug/DB08924/identifier/kegg-drug/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/drugbank/drug/DB08924/identifier/drugbank/

Statements

Subject Item
n2:DB08924
rdf:type
n3:Drug
n3:description
Amfecloral (INN), also known as amphecloral (USAN), is a stimulant drug of the phenethylamine and amphetamine chemical classes that was used as an appetite suppressant under the trade name Acutran, but is now no longer marketed. It acts as a prodrug which splits to form amphetamine and chloral hydrate, similarly to clobenzorex and related compounds, except that the N-substituent in this case yields a compound that is active in its own right. The chloral hydrate metabolite is a gabaminergic sedative/hypnotic, and would in theory counteract some of the stimulant effects of the amphetamine metabolite. This would produce an effect similar to the amphetamine/barbiturate combinations previously used in psychiatric medications. [Wikipedia]
n3:group
approved
n3:indication
Used as an appetite suppressant.
owl:sameAs
n10:DB08924
dcterms:title
Amfecloral
adms:identifier
n6:DB08924 n8:D02926
n3:synonym
Amphecloral
n3:IUPAC-Name
n4:271B5D40-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5D46-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5D45-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5D42-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5D43-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5D44-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5D3F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5D4C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5D4D-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5D47-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5D48-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5D4A-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5D49-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5D4B-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
5581-35-1
n3:Bioavailability
n4:271B5D51-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5D53-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5D54-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5D50-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5D4F-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5D52-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5D41-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5D4E-363D-11E5-9242-09173F13E4C5